Silence Therapeutics PLC (NAS:SLN)
$ 22.33 1.19 (5.63%) Market Cap: 1.04 Bil Enterprise Value: 973.87 Mil PE Ratio: 0 PB Ratio: 41.35 GF Score: 49/100

Silence Therapeutics PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 10, 2021 / 03:45PM GMT
Release Date Price: $22.43
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Hello, and once again, I'd like to welcome you to the 19th Annual Morgan Stanley Healthcare Conference. My name is David Lebowitz. I'm one of the biotechnology analysts here. Before we get going, I'm going to read the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, I'll begin. I'm happy to have in the next session with us an RNAi company named Silence Therapeutics. From the company, we have President and CEO, Mark Rothera; CFO, Craig Tooman; and Executive Vice President, Head of R&D and Chief Medical Officer, Dr. Giles Campion.

Questions & Answers

David Neil Lebowitz
Morgan Stanley, Research Division - VP

And with that, I guess, if you could start off by running us through what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot